

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

duloxetine

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 Year

Medications	Quantity Limit
Cymbalta (duloxetine) Drizalma Sprinkles (duloxetine) Irenka (duloxetine)	May be subject to quantity limit or Dose Optimization

APPROVAL CRITERIA

Requests for duloxetine (Cymbalta, Drizalma Sprinkles, Irenka) may be approved if the following criteria are met:

- I. Individual has a diagnosis of Major Depressive Disorder (MDD), Depressive disorder or Dysthymia; **AND**
- II. Individual had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) of and inadequate response or intolerance to **two** preferred antidepressants;

Preferred agents: amitriptyline HCl, amoxapine, bupropion HCl, citalopram hydrobromide, clomipramine HCl, desipramine HCl, doxepin HCl, escitalopram oxalate, fluoxetine HCl except 60mg tablets, fluvoxamine maleate tablets, imipramine HCl, imipramine pamoate, maprotiline HCl, mirtazapine, nefazadone HCL, nortriptyline HCl, paroxetine HCl, paroxetine ER, paroxetine CR, phenelzine sulfate, protriptyline HCl, sertraline HCl, tranylcypromine sulfate, trazodone HCl, trimipramine maleate, venlafaxine HCl, venlafaxine ER

OR

- III. Individual has a diagnosis of Generalized Anxiety Disorder; **AND**
- IV. Individual had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) of and inadequate response or intolerance to one of the following medications:
 - A. Venlafaxine (immediate or extended release products); **OR**
 - B. Buspirone; **OR**
 - C. Escitalopram; **OR**
 - D. Paroxetine; **OR**
 - E. Individual is 7 -18 years of age;

OR

CRX-ALL-0521-20

PAGE 1 of 4 02/24/2020

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

- V. Individual has a diagnosis of neuropathic pain associated with diabetic peripheral neuropathy; **AND**
- VI. Individual had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) of and inadequate response or intolerance to one of the following medications:
- A. Tricyclic antidepressants (AACE 2015, AAFP 2010, ADA 2017, NICE 2013); **OR**
 - B. Gabapentin (AACE 2015, ADA 2017, NICE 2013, AHFS, DRUGDex B, IIa); **OR**
 - C. Venlafaxine (immediate or extended-release products) (AACE 2015, ADA 2017); **OR**
 - D. Lyrica
- OR**
- VII. Individual has a clinical diagnosis of Fibromyalgia (for example, based upon symptoms of widespread pain, typically reported in the muscles and joints, findings of “multiple tender points” in characteristic soft tissue locations, and any disorder that would otherwise explain the pain have been excluded); **AND**
- VIII. Individual meets ALL of the following criteria:
- A. Symptoms have been present at a similar level for at least 3 months; **AND**
 - B. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) of and inadequate response or intolerance to **two** of the following medications that are FDA approved or medically accepted for the treatment of fibromyalgia:
 - 1. Tricyclic antidepressants (CFCG 2012, EULAR 2016); **OR**
 - 2. Gabapentin (CFCG 2012); **OR**
 - 3. Cyclobenzaprine(CFCG 2012, EULAR 2016); **OR**
 - 4. Fluoxetine (CFCG 2012) or alternative selective serotonin reuptake inhibitor (SSRI) (CFCG 2012); **OR**
 - 5. Savella*; **OR**
 - 6. Lyrica
- OR**
- IX. Individual has a diagnosis of chronic musculoskeletal pain (such as, chronic low back pain [CLBP] or chronic pain from osteoarthritis); **AND**
- X. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) of and inadequate response or intolerance to one of the following medications:
- A. Non-steroidal anti-inflammatory drug (NSAID) (individually or as part of a combination product); **OR**
 - B. Acetaminophen (individually or as part of a combination product); **OR**
 - C. Tramadol

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

OR

Requests for Drizalma Sprinkle (duloxetine delayed-releases capsules) may be approved based on the following criteria:

- I. Individual is unable to swallow the oral dose from due to a clinical condition such as but not limited to the following:
 - A. Dysphagia; **OR**
 - B. Individual's age.

Note:

SNRI antidepressants have a black box warning for suicidal thoughts and behaviors. Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. Use is not approved in the pediatric population. Individuals, who are started on antidepressant therapy, should be monitored closely for worsening, and emergence of suicidal thoughts and behaviors. Monitoring should especially occur during the initial few months of a course of therapy, or at times of dose changes, either increases or decreases.

*Prior authorization may be required

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2019. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: December 2, 2019
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.
5. AACE: Handelsman YY. American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocrine practice. 2015-04;21 Suppl 1:1-87.
6. American College of Rheumatology (ACR). 2010 Fibromyalgia Diagnostic Criteria. Available at : https://www.rheumatology.org/practice/clinical/classification/fibromyalgia/fibro_2010.asp. Accessed December 21, 2017.
7. American Diabetes Association. 10. Microvascular Complications and Foot Care. Diabetes Care. 2017 Jan ; 40(Suppl 1) : S88-S98. Available from: http://care.diabetesjournals.org/content/diacare/suppl/2016/12/15/40.Supplement_1.DC1/DC_40_S1_final.pdf. Accessed December 27, 2017.
8. American Psychiatric Association (APA). Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. Arlington (VA): American Psychiatric Association (APA); 2010 Oct. 152 p. [1170 references]
9. Arnold LM. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis and rheumatism. 2007-04;56:1336-1344.
10. Attal, N. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. European journal of neurology (1351-5101), 17 (9), p. 1113
11. The Canadian Fibromyalgia Guidelines Committee (CFCG). 2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome. Available from <http://fmguidelines.ca/>. Accessed January 11, 2017.
12. Dworkin RH. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clinic proceedings. 2010-03;85:S3-14.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

13. Finnerup NB. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. *Lancet neurology*. 2015-02;14:162-173. (NeuPSIG of the International Association for the Study of Pain [IASP]). Available from: http://iasp.files.cms-plus.com/AM/Images/GYAP/Neuropathic/lancet_pharmacotherapy_neuropathic_pain.pdf. Accessed January 4, 2017.
14. Häuser W. Review of pharmacological therapies in fibromyalgia syndrome. *Arthritis research & therapy*. 2014-01-17;16:201.
15. Lindsay TJ. Treating diabetic peripheral neuropathic pain. *American family physician*. 2010-07;82:151-158.
16. MacFarlane GJ, Kronisch C, Dean LE, et.al. EULAR revised recommendations for the management of fibromyalgia. *Ann Rheum Dis*. 2016; 0:1-11.
17. Moore RA. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. *Cochrane database of systematic reviews*. 2014-04-27;4:CD007938.
18. Mitchell J, Trangle M, Degnan B, Gabert T, Haight B, Kessler D, Mack N, Mallen E, Novak H, Rossmiller D, Setterlund L, Somers K, Valentino N, Vincent S. Institute for Clinical Systems Improvement. Adult Depression in Primary Care. Updated September 2013.
19. Pop-Busi R, Boulton AJM, Feldman EL, et.al. Diabetic Neuropathy: A position statement by the American Diabetes Association. *Diabetes Care*. 2017;40:136-154.
20. Trangle M, Gursky J, Haight R, Hardwig J, Hinnenkamp T, Kessler D, Mack N, Myszkowski M. Institute for Clinical Systems Improvement. Adult Depression in Primary Care. Updated March 2016. Available from: https://www.icsi.org/_asset/fnhdm3/Depr-Interactive0512b.pdf. Accessed January 20, 2017.
22. National Institute for Health and Care Excellence (NICE). Neuropathic pain - pharmacological management. The pharmacological management of neuropathic pain in adults in non-specialist settings. London (UK): National Institute for Health and Care Excellence (NICE); 2013 Nov. 41 p. (Clinical guideline; no. 173). Available from: <https://www.nice.org.uk/guidance/cg173>. Accessed January 4, 2017.
23. VA/DoD Clinical Practice Guideline for Management of Major Depressive Disorder. Department of Veterans Affairs, Department of Defense; 2008. Available from: <http://www.healthquality.va.gov/guidelines/MH/mdd/MDDFULL053013.pdf>. Accessed January 8, 2017.
24. Wolfe F. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. *Arthritis care & research* (2010). 2010-05;62:600-610.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.